ES2162035T3 - Procedimiento para el aislamiento de galantamina. - Google Patents

Procedimiento para el aislamiento de galantamina.

Info

Publication number
ES2162035T3
ES2162035T3 ES96907470T ES96907470T ES2162035T3 ES 2162035 T3 ES2162035 T3 ES 2162035T3 ES 96907470 T ES96907470 T ES 96907470T ES 96907470 T ES96907470 T ES 96907470T ES 2162035 T3 ES2162035 T3 ES 2162035T3
Authority
ES
Spain
Prior art keywords
galantamine
procedure
isolation
manufactured
alcaloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96907470T
Other languages
English (en)
Inventor
Thomas Hille
Hans-Rainer Hoffmann
Mirko Kreh
Rudolf Matusch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Application granted granted Critical
Publication of ES2162035T3 publication Critical patent/ES2162035T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION TIENE POR OBJETO UN PROCEDIMIENTO PARA AISLAR EL ALCALOIDE GALANTAMINA (FORMULA I), LA PROPIA GALANTAMINA FABRICADA SEGUN ESTE PROCEDIMIENTO, EL EMPLEO DE LA GALANTAMINA ASI FABRICADA EN PREPARACIONES GALENICAS, ASI COMO LA GALANTAMINA ASI FABRICADA PARA EL TRATAMIENTO DEL GLAUCOMA DE ANGULO CERRADO, DE LA ENFERMEDAD DE ALZHEIMER Y LA DEPENDENCIA AL ALCOHOL Y LA NICOTINA.
ES96907470T 1995-03-17 1996-03-14 Procedimiento para el aislamiento de galantamina. Expired - Lifetime ES2162035T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19509663A DE19509663A1 (de) 1995-03-17 1995-03-17 Verfahren zur Isolierung von Galanthamin

Publications (1)

Publication Number Publication Date
ES2162035T3 true ES2162035T3 (es) 2001-12-16

Family

ID=7756925

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96907470T Expired - Lifetime ES2162035T3 (es) 1995-03-17 1996-03-14 Procedimiento para el aislamiento de galantamina.
ES01100944T Expired - Lifetime ES2206356T3 (es) 1995-03-17 1996-03-14 Preparado farmaceutico con galantamina como sustancia inhibidora de la colinesterasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01100944T Expired - Lifetime ES2206356T3 (es) 1995-03-17 1996-03-14 Preparado farmaceutico con galantamina como sustancia inhibidora de la colinesterasa.

Country Status (23)

Country Link
US (5) US5877172A (es)
EP (2) EP0815112B1 (es)
JP (1) JP3863180B2 (es)
KR (1) KR100427093B1 (es)
CN (1) CN1088460C (es)
AT (2) ATE203993T1 (es)
AU (1) AU707203B2 (es)
CA (1) CA2215351C (es)
CZ (1) CZ294722B6 (es)
DE (3) DE19509663A1 (es)
DK (2) DK1095656T3 (es)
ES (2) ES2162035T3 (es)
HU (1) HU225267B1 (es)
IL (1) IL117371A (es)
MY (1) MY114698A (es)
NO (1) NO316380B1 (es)
NZ (1) NZ304008A (es)
PL (1) PL184238B1 (es)
PT (2) PT815112E (es)
SI (1) SI1095656T1 (es)
SK (1) SK283861B6 (es)
WO (1) WO1996029332A1 (es)
ZA (1) ZA962140B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US6159476A (en) * 1999-01-11 2000-12-12 Herbaceuticals Herbal supplement for increased muscle strength and endurance for athletes
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
GB9909469D0 (en) * 1999-04-23 1999-06-23 Wilkinson John A Insectidal composition
US6426097B2 (en) * 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
EP1461611B1 (en) * 2001-12-10 2010-03-03 Washington University Diagnostic for early stage alzheimer's disease
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
ATE487492T1 (de) * 2003-02-27 2010-11-15 Eisai R&D Man Co Ltd Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
FR2879599B1 (fr) * 2004-12-16 2007-03-23 Centre Nat Rech Scient Cnrse Utilisation de la chromatographie de partage centrifuge pour la purification de la galanthamine
ITMI20042413A1 (it) * 2004-12-17 2005-03-17 Indena Spa Processo per la preparazione di galantamina bromidrato
EP1858897A1 (en) * 2005-03-17 2007-11-28 Ivax Pharmaceuticals S.R.O. Isolation of galanthamine from biological material
DE602006016441D1 (de) * 2005-05-13 2010-10-07 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
CN1307180C (zh) * 2005-05-24 2007-03-28 天津大学 从石蒜或雪花莲属原料中提取加兰他敏的方法
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
US7446352B2 (en) * 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
EP2039302A3 (en) 2007-09-18 2009-06-10 Ethicon Endo-Surgery, Inc. Devices for reduction of post operative ileus
EP2330910B1 (en) * 2008-09-11 2017-08-16 Israeli Biotechnology Research Ltd. Cosmetic use of leucojum bulb extracts
US8247405B2 (en) * 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101602767B (zh) * 2009-05-26 2012-01-11 苏州派腾生物医药科技有限公司 一种加兰他敏的制备方法
DE102009040381A1 (de) 2009-09-07 2011-03-17 Kallimopoulos, Thomas, Dr. Verfahren zur Isolierung von Alkaloiden aus Pflanzen
CN101787028B (zh) * 2010-01-12 2012-01-04 恩施清江生物工程有限公司 一种从忽地笑中提取加兰他敏的方法
CN102050826B (zh) * 2010-12-21 2012-11-14 浙江工业大学 一种分离加兰他敏的方法
BG67337B1 (bg) 2018-05-23 2021-06-15 Софарма Ад Метод за получаване на пречистен галантамин хидробромид

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) * 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
EP0515301A3 (en) * 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin

Also Published As

Publication number Publication date
IL117371A (en) 2000-01-31
NO974119D0 (no) 1997-09-08
US20030012831A1 (en) 2003-01-16
US20020028802A1 (en) 2002-03-07
US5877172A (en) 1999-03-02
CN1178533A (zh) 1998-04-08
EP1095656A2 (de) 2001-05-02
AU707203B2 (en) 1999-07-08
ATE203993T1 (de) 2001-08-15
EP1095656A3 (de) 2001-05-16
ES2206356T3 (es) 2004-05-16
MY114698A (en) 2002-12-31
US6194404B1 (en) 2001-02-27
EP0815112B1 (de) 2001-08-08
PT1095656E (pt) 2004-01-30
SI1095656T1 (en) 2004-02-29
JPH11505519A (ja) 1999-05-21
NO974119L (no) 1997-09-08
CA2215351C (en) 2005-01-11
NO316380B1 (no) 2004-01-19
JP3863180B2 (ja) 2006-12-27
ATE247473T1 (de) 2003-09-15
US6573376B2 (en) 2003-06-03
WO1996029332A1 (de) 1996-09-26
DK1095656T3 (da) 2003-12-08
SK283861B6 (sk) 2004-03-02
CZ294722B6 (cs) 2005-03-16
DE59610680D1 (de) 2003-09-25
CZ283597A3 (en) 1997-12-17
MX9707015A (es) 1997-11-29
HUP9802234A3 (en) 2000-03-28
CN1088460C (zh) 2002-07-31
KR100427093B1 (ko) 2004-07-31
EP1095656B1 (de) 2003-08-20
KR19980703067A (ko) 1998-09-05
DK0815112T3 (da) 2001-11-12
PT815112E (pt) 2002-01-30
PL322463A1 (en) 1998-02-02
US6335328B2 (en) 2002-01-01
ZA962140B (en) 1996-09-16
IL117371A0 (en) 1996-07-23
HU225267B1 (en) 2006-08-28
US6617452B2 (en) 2003-09-09
DE59607450D1 (de) 2001-09-13
EP0815112A1 (de) 1998-01-07
SK123597A3 (en) 1998-02-04
HUP9802234A2 (hu) 1999-02-01
NZ304008A (en) 1998-09-24
US20010001100A1 (en) 2001-05-10
DE19509663A1 (de) 1996-09-19
PL184238B1 (pl) 2002-09-30
CA2215351A1 (en) 1996-09-26
AU5108896A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
ES2162035T3 (es) Procedimiento para el aislamiento de galantamina.
IT1262896B (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
MXPA03011625A (es) Estacion de carnada para roedores.
YU51402A (sh) Primena derivata fumarne kiseline u lečenju mitohondrijalnih bolesti
ATE216573T1 (de) Aus ölen bestehende zusammensetzung für kosmetische produkte
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
MD1315B1 (en) Oxim esters and intermediate compositions, process for preparation thereof, compositions, process for pests control.
ES2196388T3 (es) Empleo de preparados medicamentosos acuosos para la produccion de aerosoles exentos de gas propulsor.
BR0114316A (pt) Processo para a preparação de formulações em pó
NO954320D0 (no) Lyosfærer omfattende gonadotropin
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
BR0016467A (pt) Lipopeptìdeos como agentes antibacterianos
ES2089672T3 (es) N-fenilacetaminonitrilos y su empleo como productos intermedios para la sintesis de 3-aril-pirrolidin-2,4-dionas insecticidas y acaricidas.
ES2185781T3 (es) Cianofeniluracilos substituidos.
ES2180809T3 (es) Administracion sublingual y bucal de selegilina.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
ES2158327T3 (es) Derivados de benzo(g)quinolina.
ES2128557T3 (es) Derivados de poliamina como agentes radioprotectores.
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ES2151991T3 (es) Procedimiento para preparar un derivado de tieno(2,3-b)(1,5)benzodiacepina.
DK0585896T3 (da) Lægemiddel til topisk applikation i øjenområdet til behandling af forhøjet intraokulært tryk
ES2192610T3 (es) Aminouracilos substituidos.
ES2195158T3 (es) Amidas de alfa-aminoacidos, su preparacion y el uso terapeutico de las mismas.
DE60139409D1 (de) Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen
BR0110632A (pt) 2-enamino-cetonitrilas substituìdas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 815112

Country of ref document: ES